SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00293488
Recruitment Status : Completed
First Posted : February 17, 2006
Last Update Posted : June 23, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Progen Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 2008
  Study Completion Date : No date given